Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1979 2
1983 2
1984 2
1985 2
1986 3
1987 1
1988 3
1990 4
1991 4
1992 7
1993 7
1994 9
1995 5
1996 8
1997 9
1998 13
1999 12
2000 23
2001 22
2002 22
2003 23
2004 27
2005 41
2006 48
2007 49
2008 54
2009 75
2010 64
2011 63
2012 89
2013 76
2014 96
2015 103
2016 110
2017 112
2018 78
2019 53
2020 75
2021 88
2022 89
2023 79
2024 47

Text availability

Article attribute

Article type

Publication date

Search Results

1,470 results

Results by year

Filters applied: . Clear all
Page 1
Age-Related Macular Degeneration: A Review.
Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Fleckenstein M, et al. JAMA. 2024 Jan 9;331(2):147-157. doi: 10.1001/jama.2023.26074. JAMA. 2024. PMID: 38193957 Review.
IMPORTANCE: Age-related macular degeneration (AMD) affects approximately 20 million people in the US and 196 million people worldwide. AMD is a leading cause of severe vision impairment in older people and is expected to affect approximately 288 millio …
IMPORTANCE: Age-related macular degeneration (AMD) affects approximately 20 million people in the US and 196 mil …
Review of gene therapies for age-related macular degeneration.
Khanani AM, Thomas MJ, Aziz AA, Weng CY, Danzig CJ, Yiu G, Kiss S, Waheed NK, Kaiser PK. Khanani AM, et al. Eye (Lond). 2022 Feb;36(2):303-311. doi: 10.1038/s41433-021-01842-1. Epub 2022 Jan 11. Eye (Lond). 2022. PMID: 35017696 Free PMC article. Review.
We present the available data of current clinical trials for the treatment of neovascular and dry age-related macular degeneration with different AAV-based gene therapies. ...Retinal gene therapies offer the potential for life-changing treatment for ch …
We present the available data of current clinical trials for the treatment of neovascular and dry age-related macular
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Wong WL, et al. Lancet Glob Health. 2014 Feb;2(2):e106-16. doi: 10.1016/S2214-109X(13)70145-1. Epub 2014 Jan 3. Lancet Glob Health. 2014. PMID: 25104651 Free article. Review.
METHODS: We did a systematic literature review to identify all population-based studies of age-related macular degeneration published before May, 2013. Only studies using retinal photographs and standardised grading classifications (the Wisconsin ag
METHODS: We did a systematic literature review to identify all population-based studies of age-related macular degen
Age-related macular degeneration therapy: a review.
Ammar MJ, Hsu J, Chiang A, Ho AC, Regillo CD. Ammar MJ, et al. Curr Opin Ophthalmol. 2020 May;31(3):215-221. doi: 10.1097/ICU.0000000000000657. Curr Opin Ophthalmol. 2020. PMID: 32205470 Review.
PURPOSE OF REVIEW: The purpose of this review is to describe the current clinical landscape of potential future therapies for both nonexudative (dry) and exudative (wet) age-related macular degeneration (AMD). We highlight some of the more promising tr …
PURPOSE OF REVIEW: The purpose of this review is to describe the current clinical landscape of potential future therapies for both nonexudat …
Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
Liberski S, Wichrowska M, Kocięcki J. Liberski S, et al. Int J Mol Sci. 2022 Aug 20;23(16):9424. doi: 10.3390/ijms23169424. Int J Mol Sci. 2022. PMID: 36012690 Free PMC article. Review.
Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are common retinal vascular diseases responsible for most blindness in the working-age and older population in developed countries. ...Therefore, therape …
Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are common retinal v …
Mechanisms of mitochondrial dysfunction and their impact on age-related macular degeneration.
Kaarniranta K, Uusitalo H, Blasiak J, Felszeghy S, Kannan R, Kauppinen A, Salminen A, Sinha D, Ferrington D. Kaarniranta K, et al. Prog Retin Eye Res. 2020 Nov;79:100858. doi: 10.1016/j.preteyeres.2020.100858. Epub 2020 Apr 13. Prog Retin Eye Res. 2020. PMID: 32298788 Free PMC article. Review.
Oxidative stress-induced damage to the retinal pigment epithelium (RPE) is considered to be a key factor in age-related macular degeneration (AMD) pathology. RPE cells are constantly exposed to oxidative stress that may lead to the accumulation of dama …
Oxidative stress-induced damage to the retinal pigment epithelium (RPE) is considered to be a key factor in age-related mac
Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions.
Cabral de Guimaraes TA, Daich Varela M, Georgiou M, Michaelides M. Cabral de Guimaraes TA, et al. Br J Ophthalmol. 2022 Mar;106(3):297-304. doi: 10.1136/bjophthalmol-2020-318452. Epub 2021 Mar 19. Br J Ophthalmol. 2022. PMID: 33741584 Free PMC article. Review.
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. ...The approaches being investigated to reduce the rate of disease progression include, (1) drugs with antioxidative properties, (2) in
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. ..
Mechanisms of age-related macular degeneration and therapeutic opportunities.
van Lookeren Campagne M, LeCouter J, Yaspan BL, Ye W. van Lookeren Campagne M, et al. J Pathol. 2014 Jan;232(2):151-64. doi: 10.1002/path.4266. J Pathol. 2014. PMID: 24105633 Review.
As the age of the population increases in many nations, age-related degenerative diseases pose significant socioeconomic challenges. One of the key degenerative diseases that compromise quality of life is age-related macular degenerati
As the age of the population increases in many nations, age-related degenerative diseases pose significant socioeconomi …
Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches.
Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Ricci F, et al. Int J Mol Sci. 2020 Nov 3;21(21):8242. doi: 10.3390/ijms21218242. Int J Mol Sci. 2020. PMID: 33153227 Free PMC article. Review.
Age-related macular degeneration (AMD) constitutes a prevalent, chronic, and progressive retinal degenerative disease of the macula that affects elderly people and cause central vision impairment. ...
Age-related macular degeneration (AMD) constitutes a prevalent, chronic, and progressive retinal degenerative di
Lutein and Zeaxanthin and Their Roles in Age-Related Macular Degeneration-Neurodegenerative Disease.
Mrowicka M, Mrowicki J, Kucharska E, Majsterek I. Mrowicka M, et al. Nutrients. 2022 Feb 16;14(4):827. doi: 10.3390/nu14040827. Nutrients. 2022. PMID: 35215476 Free PMC article. Review.
The recommended daily intake of lutein is approximately 10.0 mg and that of zeaxanthin is 2 mg. Lutein intake in adults varies, with average intakes being 1-2 mg/day. ...It has been shown that supportive therapy with lutein and zeaxanthin can have a beneficial effec …
The recommended daily intake of lutein is approximately 10.0 mg and that of zeaxanthin is 2 mg. Lutein intake in adults varies, with …
1,470 results